Tolerance by Engaging Antigen During Cellular Homeostasis

Kidney Transplantation Clinical Trial

— TEACH  

Official title:

Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03504241
• Other study ID #: DAIT ITN062ST
• Secondary ID: UM1AI109565NIAID
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 30, 2018
• Est. completion date: December 2029

Study information

• Verified date: January 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer.

The purpose of this study is to determine if:

• it is safe to give mesenchymal stromal cells (MSCs) to kidney transplant recipients, and

• the combination of the immunosuppressive (anti-rejection) study drugs plus the MSCs can allow a kidney transplant recipient to slowly reduce and/or then completely stop all anti-rejection drugs, without rejection of their kidney (renal) allograft, a process called "immunosuppression withdrawal".

Description:

Background:The most common problem following a kidney transplant is the development of acute or chronic rejection. Rejection is the immunologic reaction in which the body refuses to accept the transplanted organ. The body's immune system will make destructive antibodies that will attempt to attack the transplanted organ.

In order to prevent organ rejection, all patients receiving an allograft (a graft transplanted between genetically non-identical individuals of the same species) must take anti-rejection (immunosuppressive) therapy. These medications function by lowering the body's natural immune system. Often these medications are associated with significant side effects ranging from infections to cancer.

Study:

This is a single center, open label, dose-escalation clinical trial in 6 adult recipients of Human Leukocyte Antigen (HLA)- non-identical, living-donor renal allografts. All participants will receive induction therapy with alemtuzumab followed by maintenance therapy with sirolimus and belatacept.

A total of 2 dosing cohorts of 2 recipients each will receive 12 infusions of donor-derived MSCs starting on Day 42 post-transplant and every 4 weeks starting on Day 56 post-transplant, with a minimum of 7 days between the first and second MSC infusions.

The primary objective is to determine whether immune reconstitution after lymphocyte depletion in the setting of co-stimulatory blockade and systemic MSC-derived donor antigen can promote operational tolerance in recipients of kidney allografts.

Participants will be evaluated for eligibility for sirolimus withdrawal any time between week 52 and week 104 post-transplant. Participants who successfully complete sirolimus withdrawal will remain on belatacept monotherapy for at least 24 weeks before being assessed for eligibility to discontinue belatacept. Participants who successfully complete Immunosuppression Withdrawal (ISW) will then undergo 24 weeks of high frequency follow up followed by 132 weeks of standard follow up.

Study participation may continue for up to seven (7) years after kidney transplant surgery.

*** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 8
• Est. completion date: December 2029
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

Recipient:

• Adult candidates of an human leukocyte antigen (HLA)-non-identical, living-donor kidney transplant:

--Candidates must meet the United Network for Organ Sharing (UNOS) criteria, including laboratory criteria, for transplant listing;

• Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing;

• Serological evidence of prior Cytomegalovirus (CMV) infection if donor is CMV positive;

• For women of child bearing potential:

• A negative serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours of start of study medication; and

• Agreement to use contraception:

--- According to the FDA Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective

----Female recipients of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for 18 months after the first dose of study therapy.

Donor:

• Meets institutional selection criteria for organ and bone marrow donation:

--All donors will be screened and tested in accordance with:

• (i) FDA 21 CRF 1271.85 requirements for donors of human cells, tissues, and cellular- and tissue-based products (HCT/P); and

• (ii) standards for living kidney donors testing for infection established by the United Network for Organ Sharing (UNOS).

• Ability to understand and provide informed consent for all study procedures including kidney transplant and bone marrow harvest.

Exclusion Criteria:

Recipient:

• History of any immunodeficiency syndrome (including Human Immunodeficiency Virus-1 (HIV-1) and HIV-2);

• Positive anti-Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR), anti-Hepatitis C Virus (HBV) PCR, or HBV surface antigen;

• History of malignancy within 5 years of enrollment or any history of hematogenous malignancy or lymphoma; --Exception: Participants with curatively treated non-melanomatous skin cancer or curatively treated cervical carcinoma in situ may be enrolled.

• Underlying renal disease with high likelihood of recurrence, including but not limited to:

• primary focal segmental glomerulosclerosis (FSGS),

• Type I or II membranoproliferative glomerulonephritis (MPGN),

• hemolytic-uremic syndrome and

• thrombotic thrombocytopenic purpura (HUS/TTP) syndrome. ---Subject(s) with end-stage renal disease (ESRD) of unknown etiology and/or has no histologically confirmed diagnosis, may be enrolled into the study as long as there are no clinical signs or symptoms consistent with excluded clinical diagnoses.

• History of active M. tuberculosis:

--Participants with a history of latent M. tuberculosis (LTB) as defined by positive testing for tuberculosis using an approved IGRA blood test, such as QuantiFERON®-Gold TB or T-SPOT-TB assay must:

• have completed treatment for LTB and

• have a negative chest x-ray. ----All participants will undergo IGRA testing for M tuberculosis within 3 months prior to transplant.

• Current or historical evidence of donor-specific antibody;

• Immunosuppressive drug therapy within one year prior to enrollment.

• May not be taking or have taken prednisone, cyclosporine A, tacrolimus, azathioprine, Mycophenolate Mofetil (MMF), cyclophosphamide, methotrexate, infliximab, etanercept, or other agents which have a primary therapeutic effect of immunosuppression in the year prior to transplantation.

• May not have taken depletional anti-lymphocyte agents at any time.

---Exceptions:

• Short (= 30 days) courses of topical or inhaled steroids are permitted, as are

• Short oral or parental pulses for a documented hypersensitivity reaction.

• Active autoimmune disease requiring ongoing immunosuppressive therapy or other conditions in which there is an anticipated need for immunosuppressive maintenance therapy;

• Uncompensated congestive heart failure, pulmonary edema, or symptomatic pulmonary hypertension;

• Active severe infection within a month of the screening visit;

• Use of an investigational drug within 30 days of the screening visit;

• Presence of any medical condition that the investigator deems incompatible with trial participation; or

• Inability or unwillingness to comply with protocol monitoring and therapy.

Donor:

• History of blood donation to the recipient;

• Evidence of prior Cytomegalovirus (CMV) infection if the recipient is CMV negative;

• History of HIV-1/HIV-2 infection;

• Positive HCV PCR, HBV PCR or HBV surface antigen;or

• Presence of any medical condition that the investigator deems incompatible with trial participation.

Related Conditions & MeSH terms

• Kidney Transplantation
• Renal Transplant Recipient
• Renal Transplantation

Intervention

Biological:
• Donor-derived Mesenchymal Stromal Cells
These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.

Drug:
• alemtuzumab
Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
• belatacept
Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
• sirolimus
Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
• mycophenolate mofetil
Per protocol, and, only permitted in cases of sirolimus intolerance.
• mycophenolate acid
Per protocol, and, only permitted in cases of sirolimus intolerance.
• prednisone
Per protocol, and, only permitted in cases of sirolimus intolerance.

Locations

Country	Name	City	State
United States	Duke University Health System	Durham	North Carolina

Sponsors (4)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Participants who Achieve Operational Tolerance	Operational tolerance (to their kidney transplant) defined by participant remaining off all immunosuppression for 52 weeks after completion of Immunosuppression Withdrawal (ISW) with: No evidence of biopsy-proven allograft rejection after initiation of ISW; Acceptable renal function, defined as an estimated GFR > 60 ml/min/1.73cm^2 calculated using the CKD-EPI equation or a serum creatinine that has increased no more than 25% above baseline, as assessed at the week 52 visit after completion of ISW; No evidence of sustained transplant renal derived pathologic proteinuria, defined as a persistent protein creatinine ratio of greater than 0.5; and; No Donor Specific Antibodies (DSA) at any time after completion of ISW.	52 weeks after completion of Immunosuppression Withdrawal (ISW)
Secondary	Proportion of Participants who Remain Off Immunosuppression	For the duration of their study participation, after completion of immunosuppression withdrawal (ISW).	From ISW completion to end of study participation (up to approximately 5 years)
Secondary	Proportion of Participants who Return to Immunosuppression	Resumption of immunosuppressive therapy post completion of Immunosuppression Withdrawal (ISW), per standard of care.	From ISW completion to end of study participation (up to approximately 5 years)
Secondary	Proportion of Participants who Achieve Belatacept Monotherapy	Belatacept monotherapy, defined as remaining on belatacept as the sole maintenance regimen for 48 weeks with: No evidence of biopsy-proven allograft rejection, while on belatacept monotherapy; Acceptable renal function, defined as an estimated GFR > 60 ml/min/1.73m^2 calculated using the CKD-EPI equation or a serum creatinine that has increased no more than 25% above baseline, as assessed at week 48 on belatacept monotherapy; No evidence of sustained transplant renal derived pathologic proteinuria, defined as a persistent protein creatinine ratio of greater than 0.5, while on belatacept monotherapy; and; No Donor Specific Antibodies (DSA) at any time while on belatacept monotherapy.	48 weeks from the time of last sirolimus dose
Secondary	Proportion of Participants who Die	This analysis will include all participants who provide informed consent for study participation and receive any form of study therapy including alemtuzumab, sirolimus, belatacept, or MSC infusions.	From kidney transplant with alemtuzumab induction to to completion of study (up to approximately 6.5 years)
Secondary	Time from Transplant to the First Episode of Rejection	Kaplan-Meier Analysis of time-to-occurrence to the first episode of kidney allograft rejection.	From kidney transplantation to completion of study (up to approximately 7 years)
Secondary	Incidence of Participants who Develop Donor Specific Antibody (DSA)	Participants that Develop de novo Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA).	From study enrollment to completion of study (up to approximately 7 years)
Secondary	Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration	According to medical assessment/outcomes, investigator's brochure for MSCs, literature et al.	From initial MCS infusion (day 42 post kidney transplant) to end of study participation (up to 7 years)
Secondary	Frequency of Select Adverse Events (AEs)	Select AEs include: Infection; Malignancy; Wound complications, defined as wound dehiscence, hernia or lymphocele	From kidney transplantation to completion of study (up to approximately 7 years)
Secondary	Incidence of Post-Transplant Diabetes	New onset diabetes status post transplant (posttransplantation diabetes mellitus [PTDM])	From post kidney transplantation to completion of study (up to approximately 7 years)
Secondary	Frequency of Antibody-Mediated Acute Cellular Rejection	Using the 2017 Banff Classification of Renal Allograft Pathology.	From kidney transplant to completion of study (up to approximately 7 years)
Secondary	Frequency of Antibody-Mediated Chronic Rejection	Using the 2017 Banff Classification of Renal Allograft Pathology.; As measured by the incidence of biopsy-proven chronic allograft nephropathy/IF/TA	From kidney transplant to completion of study (up to approximately 7 years)

External Links

•   Division of Allergy, Immunology, and Transplantation (DAIT) website
•   Immune Tolerance Network (ITN) website
•   ITN's website for the study
•   National Institute of Allergy and Infectious Diseases (NIAID) website